Related Experiment Videos
Serum gamma-seminoprotein determination in prostatic cancer
J Shimazaki1, S Akimoto, K Akakura
1Department of Urology, School of Medicine, Chiba University.
Hinyokika Kiyo. Acta Urologica Japonica
|April 1, 1991
Summary
Serum gamma-seminoprotein (gamma-Sm) shows promise as a new biomarker for prostate cancer detection. Its higher sensitivity and positive rate compared to prostatic acid phosphatase (PAP) suggest it could improve early diagnosis.
Area of Science:
- Oncology
- Biochemistry
- Urology
Background:
- Prostate cancer diagnosis relies on biomarkers.
- Prostatic acid phosphatase (PAP) is a traditional marker.
- New markers are needed for improved prostate cancer detection.
Purpose of the Study:
- To evaluate serum gamma-seminoprotein (gamma-Sm) as a novel biomarker for prostate cancer.
- To compare the efficacy of gamma-Sm against prostatic acid phosphatase (PAP).
Main Methods:
- Serum samples were analyzed for gamma-Sm and PAP levels.
- Sensitivity and specificity were calculated for both markers in untreated prostate cancer and benign prostatic hypertrophy (BPH).
- Correlation between gamma-Sm and PAP was assessed.
Main Results:
- Gamma-Sm demonstrated a higher sensitivity (81%) than PAP (67%) for untreated prostate cancer.
- Gamma-Sm showed a higher positive rate in prostate cancer across all stages compared to BPH.
- Simultaneous measurement of gamma-Sm and PAP improved overall sensitivity.
- Specificities for BPH were comparable (gamma-Sm: 87%, PAP: 90%).
- Gamma-Sm normalized more frequently than PAP after endocrine therapy for stage D2 cancer.
Conclusions:
- Serum gamma-Sm is a valuable new biomarker for prostate cancer.
- Gamma-Sm offers improved sensitivity and detection rates compared to PAP.
- Combined use of gamma-Sm and PAP may enhance diagnostic accuracy.